|
1
|
Crinò L, Dansin E, Garrido P, Griesinger
F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL
and Zhou C: Safety and efficacy of first-line bevacizumab-based
therapy in advanced non-squamous non-small-cell lung cancer (SAiL,
MO19390): A phase 4 study. Lancet Oncol. 11:733–740. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lynch TJ Jr, Spigel DR, Brahmer J,
Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ,
Fish S, et al: Safety and effectiveness of bevacizumab-containing
treatment for non-small-cell lung cancer: Final results of the
ARIES observational cohort study. J Thorac Oncol. 9:1332–1339.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lara PN Jr, Redman MW, Kelly K, Edelman
MJ, Williamson SK, Crowley JJ and Gandara DR: Southwest Oncology
Group: Disease control rate at 8 weeks predicts clinical benefit in
advanced non-small cell lung cancer: Results from Southwest
Oncology Group randomized trials. J Clin Oncol. 26:463–467. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyazaki M, Naoki K, Sato T, Tanaka K,
Tsuzuki K, Yoshida S, Tomomatsu K, Tasaka S, Soejima K, Sayama K
and Asano K: A case of advanced lung adenocarcinoma with cavity
formation shrunken by bevacizumab added on the 3rd course of
6th-line chemotherapy. Gan To Kagaku Ryoho. 39:421–424. 2012.(In
Japanese). PubMed/NCBI
|
|
6
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naoki K, Soejima K, Okamoto H, Hamamoto J,
Hida N, Nakachi I, Yasuda H, Nakayama S, Yoda S, Satomi R, et al:
The PCR-invader method (structure-specific 5′ nuclease-based
method), a sensitive method for detecting EGFR gene mutations in
lung cancer specimens; comparison with direct sequencing. Int J
Clin Oncol. 16:335–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
|
|
10
|
Niho S, Kunitoh H, Nokihara H, Horai T,
Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K,
et al: Randomized phase II study of first-line
carboplatin-paclitaxel with or without bevacizumab in Japanese
patients with advanced non-squamous non-small-cell lung cancer.
Lung Cancer. 76:362–367. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang JC, Wu YL, Schuler M, Sebastian M,
Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, et al:
Afatinib versus cisplatin-based chemotherapy for EGFR
mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):
Analysis of overall survival data from two randomised, phase 3
trials. Lancet Oncol. 16:141–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seto T, Kato T, Nishio M, Goto K, Atagi S,
Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al:
Erlotinib alone or with bevacizumab as first-line therapy in
patients with advanced non-squamous non-small-cell lung cancer
harbouring EGFR mutations (JO25567): An open-label, randomised,
multicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ichihara E, Hotta K, Nogami N, Kuyama S,
Kishino D, Fujii M, Kozuki T, Tabata M, Harada D, Chikamori K, et
al: Phase II trial of gefitinib in combination with bevacizumab as
first-line therapy for advanced non-small cell lung cancer with
activating EGFR gene mutations: The Okayama Lung Cancer Study Group
Trial 1001. J Thorac Oncol. 10:486–491. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Okabe T, Okamoto I, Tamura K, Terashima M,
Yoshida T, Satoh T, Takada M, Fukuoka M and Nakagawa K:
Differential constitutive activation of the epidermal growth factor
receptor in non-small cell lung cancer cells bearing EGFR gene
mutation and amplification. Cancer Res. 67:2046–2053. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu JQ, Zhong WZ, Zhang GC, Li R, Zhang
XC, Guo AL, Zhang YF, An SJ, Mok TS and Wu YL: Better survival with
EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small
cell lung cancer patients is due to differential inhibition of
downstream signals. Cancer Lett. 265:307–317. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Reinmuth N, Jauch A, Xu EC, Muley T,
Granzow M, Hoffmann H, Dienemann H, Herpel E, Schnabel PA, Herth
FJ, et al: Correlation of EGFR mutations with chromosomal
alterations and expression of EGFR, ErbB3 and VEGF in tumor samples
of lung adenocarcinoma patients. Lung Cancer. 62:193–201. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li H, Takayama K, Wang S, Shiraishi Y,
Gotanda K, Harada T, Furuyama K, Iwama E, Ieiri I, Okamoto I and
Nakanishi Y: Addition of bevacizumab enhances antitumor activity of
erlotinib against non-small cell lung cancer xenografts depending
on VEGF expression. Cancer Chemother Pharmacol. 74:1297–1305. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakade J, Takeuchi S, Nakagawa T, Ishikawa
D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, et al:
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of
HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR
mutation. J Thorac Oncol. 9:775–783. 2014. View Article : Google Scholar : PubMed/NCBI
|
